Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 212

Three Small CRISPR Biotechs That Could Cure 10,000 Diseases

Investor’s Business Daily looked at three small biotech companies that appear to be leading the CRISPR race.

Read More »

Three Hottest Areas of Drug Development to Keep an Eye on in 2018

The last several years has shown a particular focus on immuno-oncology therapies, probably as close to miracle cures as anything seen in recent years. Arpita Dutt, writing for Zacks, predicts what the three hot areas for approvals are likely to be in 2018.

Read More »

reMYND Forges 350M+ Euros Tie-Up With Novo Nordisk

Belgium-based reMYND’s pre-clinical diabetes therapy ReS39 will get a significant boost after the company entered a licensing agreement with noted European diabetes company Novo Nordisk.

Read More »

Nanotech, gene editing used to edit cholesterol gene: U.S. study

U.S. researchers have used nanotechnology plus the powerful CRISPR-Cas9 gene editing tool to turn off a key cholesterol-related gene in mouse liver cells.

Read More »

Boehringer, MiNA Therapeutics Forge NASH Deal

Boehringer Ingelheim struck a deal targeting liver disease with MiNA Therapeutics.

Read More »

Mallinckrodt Pays $117 Million for Bay Area Biotech Ocera, Failed Liver Drug

Staines-Upon-Thames, UK-based Mallinckrodt agreed to buy Redwood City, Calif.-based Ocera Therapeutics in a deal that could hit $117 million.

Read More »

Gilead Shows Off Mid-Stage NASH Data

Gilead Sciences released results from a Phase II clinical trial of GS-0976 for nonalcoholic steatohepatitis (NASH).

Read More »

Boehringer Ingelheim partners with TARGET PharmaSolutions to Progress NASH Research

TARGET PharmaSolutions Inc. – a real-world clinical data company – and Boehringer Ingelheim International GmbH entered into a multi-year strategic partnership for TARGET-NASH, a longitudinal observational study that evaluates patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).

Read More »

Takeda Leaps Into NASH With $470M-Plus Deal With HemoShear Therapeutics

Takeda Pharmaceutical is jumping into the $40 billion market for nonalcoholic steatohepatitis (NASH) and other diseases of the liver with a $470+ million investment into Virginia-based HemoShear Therapeutics LLC.

Read More »

Deaths, Serious Liver Injury Linked to Ocaliva

The FDA warned health-care providers to stick to dosing recommendations for Intercept Pharma’s liver disease medicine Ocaliva after 19 patient deaths were reported.

Read More »

Nestle invests in microbiome diagnostics venture

Nestle is investing 20 million euros in a joint venture with Enterome SA to develop microbiome-based diagnostics for inflammatory bowel and liver diseases.

Read More »

Novartis advances with push on cancer and liver disease

Novartis’ push into oncology and liver disease, two of its treatment priorities, advanced as the Swiss drugmaker won a second U.S. breakthrough tag for its cancer gene therapy while striking a separate pact with Allergan.

Read More »

Allergan to buy Acelity’s tissue unit LifeCell

Drugmaker Allergan Plc said it would buy LifeCell – a regenerative medicine unit owned by privately held Acelity LP Inc. – for $2.9 billion in cash.

Read More »

Intercept’s liver drug wins conditional EU approval

Intercept Pharmaceuticals Inc. said its liver drug received conditional approval from the European Commission to treat patients with primary biliary cholangitis (PBC).

Read More »

Gilead Racks Up Clinical Failures in Q3 Report

Investors were not particularly happy with Gilead’s Q3 2016 report. In addition to sagging sales and revenue, it outlined a laundry list of failed clinical trials.

Read More »

Intercept’s liver drug gets conditional backing of EMA panel

Drugmaker Intercept Pharmaceuticals Inc.’s drug to treat a rare liver condition was conditionally approved an advisory committee to the European Medicines Agency.

Read More »

Gilead Terminates Ulcerative Colitis Drug Study

Following a disappointing review of interim data from a clinical study of GS-5745, an investigational anti-MMP9 antibody, Gilead said the company will halt the trial.

Read More »

Special Feature: First Year After Launch

The new generation of hep C drugs has completely changed the conversation about launches.

Read More »

2016 Annual Report: State Of The Bio Industry

The outlook remains bright due to a favorable regulatory arena, support for biopharma-friendly legislation and development incentives, expanding scientific opportunities in key therapeutic areas such as immuno-oncology, and big pharma’s continued push to obtain innovation.

Read More »

Intercept Pharma’s Liver Drug Wins Accelerated Approval by the FDA

FDA granted accelerated approval to Ocaliva, the first new medicine for primary biliary cholangitis in nearly 20 years.

Read More »

Page 1 of 212

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation